U.S. Stock Earnings Reports & Market News
Universal Health Services FY2024 Revenue $15.83B Up 11.1%
Executive Summary
Universal Health Services (UHS), a leading provider of healthcare services, reported total revenues of $15.83 billion for FY2024, representing an increase of approximately 11.1% compared to FY2023. The company’s net income attributable to UHS was $1.14 billion, a significant growth driven by higher patient volumes and improved operational efficiencies. The company’s balance sheet shows strong liquidity with cash and cash equivalents totaling $125.98 million and total assets of $14.47 billion. The debt profile remains substantial, with long-term debt at $4.46 billion, but the company maintains a healthy leverage ratio. Cash flow from operating activities surged to over $2.07 billion, supporting ongoing capital expenditures and share repurchases. Overall, UHS demonstrates robust financial health and growth momentum, though it faces ongoing legal and regulatory risks that could impact future performance.
Key Metrics
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Total Revenue ($ billions) | 15.83 | 14.28 | +11.1% |
| Net Income ($ millions) | 1,142.1 | 717.8 | +59.3% |
| Operating Cash Flow ($ millions) | 2,067.1 | 1,267.8 | +62.9% |
| Total Assets ($ billions) | 14.47 | 13.97 | +3.6% |
| Long-term Debt ($ billions) | 4.46 | 4.79 | -6.8% |
| Cash & Equivalents ($ millions) | 125.98 | 119.44 | +5.5% |
Management Discussion and Analysis
UHS experienced a strong revenue growth of 11.1% driven primarily by increased patient volumes across its hospital network and favorable payer mix. Operating expenses increased proportionally, but the company managed to improve operating margins, resulting in a 59.3% rise in net income. The surge in operating cash flow to over $2.07 billion underscores the company’s efficient cash management and ability to fund capital investments and share repurchases. The balance sheet remains solid with assets growing modestly, while debt levels decreased slightly, reflecting ongoing debt repayment efforts. The company continues to face legal challenges and regulatory scrutiny, which could pose risks to future earnings. Nonetheless, the outlook remains positive given the company’s diversified healthcare services and strategic initiatives.
Income Statement Analysis
Revenue increased from $14.29 billion in FY2023 to $15.83 billion in FY2024, a growth of 11.1%. Gross profit margins improved slightly due to operational efficiencies. Operating income rose significantly, supported by higher revenues and controlled operating expenses. Net income attributable to UHS grew by 59.3%, reaching $1.14 billion, with EPS increasing from $10.23 to $16.82 on a diluted basis. The YoY growth reflects strong operational performance and effective cost management. QoQ comparisons also indicate consistent growth momentum, although legal and regulatory risks remain a concern.
Balance Sheet Analysis
Cash and cash equivalents increased by 5.5% to $125.98 million, providing liquidity for ongoing operations. Accounts receivable declined slightly, indicating improved collection efficiency. Total assets grew by 3.6% to $14.47 billion, mainly driven by higher cash and receivables. Long-term debt decreased by 6.8% to $4.46 billion, reflecting debt repayment activities. Equity increased to $6.75 billion, supported by retained earnings and share repurchases. The company’s leverage ratio remains within acceptable limits, supporting its credit profile.
Cash Flow Analysis
Operating cash flow surged by 62.9% to $2.07 billion, primarily due to higher net income and working capital improvements. Capital expenditures increased to support facility upgrades and new projects, while share repurchases totaled approximately $598.5 million, reducing outstanding shares. Debt repayment was significant, with net reductions in borrowings, maintaining a strong liquidity position. Dividends of $53.3 million were paid, consistent with prior periods, reflecting stable shareholder returns.
Ratios & DuPont Analysis
Net profit margin improved to approximately 7.2%, driven by higher net income. Return on assets (ROA) increased to 7.9%, indicating efficient asset utilization. Return on equity (ROE) rose to 16.9%, supported by profit growth and share repurchases. Asset turnover remained stable at around 1.1, while the equity multiplier was approximately 2.15, reflecting moderate leverage. The DuPont analysis confirms the company’s effective management of profitability, asset efficiency, and leverage.
Risk Factors
UHS faces ongoing legal risks from malpractice and other litigation, which could result in material damages and reputational harm. Regulatory risks include compliance with healthcare laws, reimbursement policies, and licensing requirements, which could impact revenue streams. Market competition from other healthcare providers and consolidation trends pose strategic challenges. Operational risks include staffing shortages and facility management issues. Macroeconomic factors such as inflation, interest rate fluctuations, and economic downturns could affect patient volumes and reimbursement rates. Cybersecurity threats remain a concern, with potential data breaches impacting patient privacy and incurring costs.
Notes & Additional Commentary
Unusual items include a pre-tax asset impairment charge of approximately $58 million in FY2022 related to Desert Springs Hospital, which was discontinued as an inpatient facility. The company’s legal provisions increased due to recent verdicts and ongoing litigations, notably the substantial damages awarded in the Pavilion and Cumberland cases. Share repurchase activity was robust, with approximately 13.5 million shares repurchased over three years, reflecting confidence in the company’s valuation. The company’s strategic investments in new facilities and technology are expected to support future growth, though legal and regulatory uncertainties could temper outlook.
Investment Implications
UHS presents a compelling growth story with strong revenue and profit expansion, supported by operational efficiencies and strategic capital deployment. Short-term opportunities include capitalizing on favorable payer mix and expanding outpatient services. Long-term risks involve legal liabilities, regulatory changes, and market competition. The company’s disciplined debt management and share repurchase program enhance shareholder value. Investors should monitor legal developments and regulatory reforms, but overall, UHS remains a resilient and attractive investment in the healthcare sector.